{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=10",
    "query": {
      "intervention": "Dose C",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 3877,
    "total_pages": 388,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T20:51:01.423Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01974063",
      "title": "Alternate Nicotine Delivery Systems and Airway Epithelial Biology",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Smoking",
        "Smoking Cessation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2013-03",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01974063"
    },
    {
      "nct_id": "NCT05482893",
      "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Biliary Tract Cancer (BTC)",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Spevatamig (PT886)",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA® (pembrolizumab)",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "CAPOX",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "TAS 102",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Combined With Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "NALIRIFOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phanes Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2023-03-15",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482893"
    },
    {
      "nct_id": "NCT00950404",
      "title": "Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Viagra 50 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Formulation B ODT tablet 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Formulation C ODT tablet 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Formulation D ODT tablet 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-08",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00950404"
    },
    {
      "nct_id": "NCT00076063",
      "title": "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP1452)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LIPO-5",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 174,
      "start_date": "2004-03",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076063"
    },
    {
      "nct_id": "NCT05296733",
      "title": "A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Liver Diseases",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "BI 456906",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 82,
      "start_date": "2022-04-27",
      "completion_date": "2023-12-29",
      "has_results": false,
      "last_update_posted_date": "2024-08-15",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 5,
      "location_summary": "Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05296733"
    },
    {
      "nct_id": "NCT01996852",
      "title": "Improving Erectile Function and Quality of Life After Prostate Cancer Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Erectile Dysfunction Following Radical Prostatectomy",
        "Erectile Dysfunction Following Simple Prostatectomy",
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "Cognitive-behavioral Meetings",
          "type": "BEHAVIORAL"
        },
        {
          "name": "sildenafil citrate",
          "type": "DRUG"
        },
        {
          "name": "Vacuum Constriction Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2013-07",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-05-10",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996852"
    },
    {
      "nct_id": "NCT01297543",
      "title": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myeloid Leukemia",
        "Myelodysplasia"
      ],
      "interventions": [
        {
          "name": "human myeloid progenitor cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Cellerant Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2011-03",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • San Francisco, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Beech Grove",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01297543"
    },
    {
      "nct_id": "NCT04175925",
      "title": "A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "BMS-986322",
          "type": "DRUG"
        },
        {
          "name": "BMS-986322 Placebo",
          "type": "OTHER"
        },
        {
          "name": "famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 171,
      "start_date": "2019-11-15",
      "completion_date": "2021-07-13",
      "has_results": false,
      "last_update_posted_date": "2022-05-31",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04175925"
    },
    {
      "nct_id": "NCT00088452",
      "title": "Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Absence Epilepsy",
        "Petit Mal Epilepsy",
        "Epilepsy",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Ethosuximide",
          "type": "DRUG"
        },
        {
          "name": "Lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "Valproic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "30 Months to 13 Years"
      },
      "enrollment_count": 453,
      "start_date": "2004-07",
      "completion_date": "2016-08-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088452"
    },
    {
      "nct_id": "NCT04220684",
      "title": "Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplant Recipient",
        "Blasts 10 Percent or More of Bone Marrow Nucleated Cells",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sumithira Vasu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2020-06-11",
      "completion_date": "2024-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-19T20:51:01.423Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Portland, Oregon",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04220684"
    }
  ]
}